CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 7176 result(s)

liraglutide (Saxenda)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: liraglutide
Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

  • Brand Name: Saxenda
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0668-000
  • Project Status: Active
  • Submission Type: Initial

encorafenib (Braftovi)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: encorafenib
Indications: In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, after prior therapy.

  • Brand Name: Braftovi
  • Manufacturer: Pfizer Canada ULC
  • Project Number: PC0233-000
  • Project Status: Active
  • Submission Type: Initial

COVID-19 Update

Last Updated: February 1, 2021
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 Evidence Portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and increasing international scientific evidence related t...

azacitidine (Onureg)

Last Updated: January 29, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: azacitidine
Indications: ​Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT).

  • Brand Name: Onureg
  • Manufacturer: Bristol-Myers Squibb Company
  • Project Number: PC0245-000
  • Project Status: Pending
  • Submission Type: Initial

Workshop - Designing Research to Inform Decision-Making Using Value of Information Analyses

Event Date: January 27, 2021
Result type: Events

Audience: Of interest to policy-makers. Level: Intermediate. What you’ll learn: This workshop introduces four value of information (VoI) measures and highlights how VoI can determine research priorities that support decision-making. The assumptions of a VoI analysis and methods to display results graphically will also be presented. Dr. Anna...

semaglutide (Rybelsus)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: semaglutide
Indications: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes

  • Brand Name: Rybelsus
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0637-000
  • Project Status: Active
  • Submission Type: Initial

esketamine hydrochloride (Spravato)

Last Updated: December 18, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: esketamine hydrochloride
Indications: Indicated in combination with a SSRI or SNRI, for the treatment of major depressive disorder in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode.

  • Brand Name: Spravato
  • Manufacturer: Janssen Inc.
  • Project Number: SR0621-000
  • Project Status: Active
  • Submission Type: Initial

Chronic Lymphocytic Leukemia

Last Updated: January 26, 2021
Result type: Reports

Provisional Funding Algorithm Stakeholder Input Deadline Feb 9, 2021 Draft Report Posted (Target) Mar 31, 2021 Stakeholder Feedback Deadline Apr 8, 2021 Final Report Posted (Target) Apr 30, 2021

  • Project Number: PH0004-000